Dozens of commonly prescribed medications can cause peripheral neuropathy, ranging from chemotherapy drugs and antibiotics to cholesterol-lowering statins and heart medications. Drug-induced neuropathy accounts for roughly 2% to 4% of all neuropathy cases, but identifying it matters because the nerve damage is often reversible if caught early enough.
How Drug-Induced Neuropathy Feels
Regardless of which medication triggers it, drug-induced neuropathy follows a fairly predictable pattern. It typically starts in the longest nerves first, which means symptoms begin in the feet and hands and spread inward. Doctors call this a “stocking-glove” distribution because the affected area mirrors where socks and gloves would sit.
The most common symptoms are numbness, tingling, burning pain, and gradual loss of sensation in the fingers and toes. As it progresses, you may notice weakness in the feet (sometimes leading to foot drop or difficulty walking), grip problems in the hands, and muscle wasting in the lower legs. Some people also develop autonomic symptoms like dizziness when standing up, which reflects damage to the nerves that regulate blood pressure and circulation.
Chemotherapy Drugs
Chemotherapy is the most well-known cause of drug-induced neuropathy, affecting roughly 30% to 60% of cancer patients. Six major classes of chemotherapy agents are responsible: platinum-based drugs, taxanes, vinca alkaloids, proteasome inhibitors, immunomodulatory drugs, and epothilones.
Platinum-based drugs like oxaliplatin are particularly aggressive. Acute nerve symptoms appear during the first few infusions in 85% to 95% of patients. Taxanes (used for breast, lung, and ovarian cancer) and vinca alkaloids both work by disrupting the internal scaffolding of cells, called microtubules. Nerve cells depend on this scaffolding to transport nutrients along their long fibers, so when it breaks down, the farthest ends of the nerves degrade first. This is why symptoms start in the fingers and toes and work their way inward, a process researchers describe as “dying back” neuropathy.
Platinum drugs damage nerves differently. Rather than disrupting the cell’s scaffolding, they interfere with DNA inside the nerve cell body itself, triggering a cascade of oxidative stress and dysfunction in the cell’s energy-producing structures. The result is the same: progressive numbness and pain that can persist long after treatment ends.
Antibiotics
Several antibiotics carry neuropathy risk, but fluoroquinolones stand out. This class, which includes ciprofloxacin, levofloxacin, and moxifloxacin, has the strongest statistical association with nerve damage among all antibiotics studied. In a large adverse-event database analysis, fluoroquinolones had a reporting odds ratio of 17.6 for peripheral neuropathy, far higher than any other antibiotic class.
The FDA issued a safety communication warning that fluoroquinolone-related neuropathy can begin soon after starting the drug and may be permanent. It can also develop at any point during treatment and persist for months to years after stopping. This risk applies only to oral or injectable forms, not to ear or eye drops. If neuropathy symptoms develop, the recommendation is to stop the fluoroquinolone immediately.
Other antibiotics linked to neuropathy include nitrofurantoin (commonly prescribed for urinary tract infections), metronidazole (used for certain bacterial and parasitic infections), and linezolid (a powerful antibiotic reserved for resistant infections). More recently, cefoxitin and amikacin have also been flagged as potential causes.
Statins
The relationship between cholesterol-lowering statins and neuropathy is genuinely complicated. An influential case-control study published in Neurology found that statin users had roughly 3.7 times the odds of developing unexplained neuropathy compared to non-users. For people on statins for two or more years, the odds ratio climbed to 26.4 for confirmed cases.
However, a large 2025 meta-analysis published in The Lancet, drawing on blinded randomized controlled trials, found no significant excess risk of peripheral neuropathy from statin therapy. The discrepancy likely reflects the difference between observational studies (which can be influenced by other health factors common in statin users, like diabetes) and controlled trials. The current consensus is that if statins do cause neuropathy, the risk is small and likely concentrated in people who already have other risk factors for nerve damage.
Heart and Blood Pressure Medications
Amiodarone, a drug used to treat irregular heart rhythms, is one of the better-documented cardiovascular causes of neuropathy. It tends to cause a slowly progressive sensory neuropathy that can develop after months of use. Hydralazine, an older blood pressure medication, has also been associated with nerve damage, though it is prescribed less frequently today. Colchicine, used for gout but sometimes prescribed alongside heart medications, carries its own neuropathy risk with prolonged use.
HIV Medications
Older antiretroviral drugs are a significant cause of neuropathy in people living with HIV. The worst offenders are nucleoside reverse transcriptase inhibitors, specifically stavudine, didanosine, and zalcitabine. These drugs cause cumulative damage to the energy-producing structures inside nerve cells and increase harmful oxidative stress. Some protease inhibitors (indinavir, ritonavir, saquinavir) may also contribute, though their effect is thought to be indirect, possibly through metabolic disturbances like insulin resistance rather than direct nerve toxicity.
Modern HIV treatment regimens have largely moved away from these problematic drugs, but neuropathy remains common in people who took them in earlier years of their treatment.
Other Medications to Be Aware Of
The list of neuropathy-linked drugs extends well beyond the major categories. Additional medications that have been associated with nerve damage include:
- Phenytoin (seizure medication), with long-term use
- Isoniazid and ethambutol (tuberculosis drugs)
- Disulfiram (used for alcohol dependence)
- Dapsone (used for certain skin conditions and infections)
- Thalidomide (used for multiple myeloma and other conditions)
- High-dose vitamin B6 (pyridoxine), which paradoxically damages the same nerves that B6 deficiency harms
- Gold compounds (older rheumatoid arthritis treatment)
- Chloroquine (antimalarial)
Who Is Most Vulnerable
Not everyone taking these medications will develop neuropathy. Pre-existing diabetes is one of the strongest risk factors, because nerves already under metabolic stress are more susceptible to additional toxic injury. Interestingly, even the treatment of diabetes itself can trigger neuropathy. Rapidly lowering blood sugar in someone with a history of poor glucose control can cause a condition called treatment-induced neuropathy of diabetes. This tends to affect younger patients (around age 35), predominantly men with type 1 diabetes diagnosed roughly five years earlier. The mechanism likely involves microcirculation changes that can’t keep pace with the rapid glucose correction.
Other factors that raise your risk include higher cumulative drug doses, longer duration of treatment, pre-existing nerve damage from any cause, kidney impairment (which slows drug clearance), and concurrent use of multiple neuropathy-causing medications.
Reversibility Depends on Timing
The single most important factor in recovery is how much nerve damage has accumulated before the offending drug is stopped. Drug-induced neuropathy is considered a potentially reversible condition, but that window closes as nerve fibers sustain deeper injury. When the damage is limited to the protective coating around nerve fibers (the myelin sheath), recovery over weeks to months is common. When the nerve fibers themselves have degenerated, recovery is slower, partial, or in some cases permanent.
Fluoroquinolone neuropathy is a notable exception to the optimistic picture. The FDA warning specifically flags the potential for permanent damage, and some patients report symptoms lasting years after discontinuation. Chemotherapy-induced neuropathy also frequently persists, with many cancer survivors dealing with residual numbness and pain long after completing treatment.
If you’re taking any of these medications and notice new tingling, numbness, or pain in your hands or feet, raising the issue early gives you the best chance of preventing irreversible damage. In many cases, switching to an alternative medication or adjusting the dose is enough to halt progression and allow nerves to recover.